Together, the present findings support the possibility that uPA/uPAR activation in response to high glucose participates in the mechanisms causing DN and provide evidence that the uPAR pathway is a promising target for the development of novel multitarget drugs in the treatment of diabetic kidney disease. Here, PLAUR is linked to liver dysplastic nodule.